Pediatric Hematology/Oncology, City of Hope National Medical Center, Duarte, California, USA
The proposed study will investigate new treatment modalities in the field of hematopoietic stem cell transplantation. I have a vast experience in cellular therapy, in its unrefined mode of hematopoietic stem cell transplantation, as well as in more selective cell therapeutics, such as CD34+ haploidentical transplant and CD8+ modified T cells in treatment of neuroblastoma, and most recently, in the early development phases of a study investigating modification of central memory derived CD19-specific T-cell grafts in patients with childhood CD19+ ALL. In my role as the director of a pediatric BMT unit, I have the expertise, leadership and motivation necessary to successfully carry out this project. As a board certified pediatric hematologist/oncologist I have a broad exposure to pre-B cell ALL, the most common cancer diagnosis in childhood. I have served as the PI on multiple clinical trials involving all sources of hematopoietic stem cells. Currently, I am the PI on trials involving cord blood transplants, haploidentical transplants, and clinical trials utilizing novel devices employed in conditioning therapy. In my role as PI it is my responsibility to oversee the administration of the projects, including and not limited to: staffing, research protections, budget, collaboration with other investigators, and publication of peer-reviewed manuscripts from each project. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget. The current application builds on my prior work, as a clinical investigator. I have a demonstrated track record of successful and productive research projects in the area of cellular therapy. I am confident that my experience has prepared me to lead the proposed project.
To investigate new treatment modalities in the field of hematopoietic stem cell transplantation.
Cellular therapy and its unrefined mode of hematopoietic stem cell transplantation.